Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 19, 2020, details a strategic collaboration between Precision BioSciences, Inc. (the "Company") and Eli Lilly and Company ("Lilly"). The Company, an emerging growth company incorporated in Delaware, focuses on in vivo gene editing using its proprietary ARCUS nucleases platform.
Key Financial Metrics and Transaction Details
The filing discloses a significant capital infusion and revenue agreement rather than standard periodic financial results (revenue, profit, cash flow).
- Upfront Cash Payment: $100 million to be received upon closing.
- Equity Investment: $35 million from Lilly via a private placement of 3,762,190 shares of common stock.
- Share Price: Approximately $9.30 per share (a 25% premium over the 30-day VWAP).
- Projected Cash Runway: The combined payments are projected to extend the Company's cash runway into 2023.
- Future Milestones: Eligible to receive up to $420 million in milestone payments per licensed product.
- Royalties: Tiered royalties ranging from mid-single digits to low-teens percentages on worldwide net sales.
Material Changes and Agreement Terms
The Company entered into a Development and License Agreement and a Stock Purchase Agreement with Lilly on November 19, 2020.
- Scope: Collaboration to discover and develop in vivo gene editing products for genetic disorders, initially targeting Duchenne muscular dystrophy and two other gene targets.
- Roles: Precision BioSciences will conduct pre-clinical research and IND-enabling activities. Lilly will handle clinical development and commercialization.
- Exclusivity: Lilly receives an exclusive license for nominated gene targets. The Company cannot collaborate with third parties on these targets during the term.
- Lock-up Period: Lilly is restricted from selling the acquired shares for nine months following the Effective Date.
Outlook, Risks, and Contingencies
Management expects the collaboration to yield commercially successful products, though these are forward-looking statements subject to risks.
- Regulatory Approval: Transactions are subject to customary closing conditions, including the expiration of the Hart-Scott-Rodino Antitrust waiting period.
- Termination Rights: Lilly may terminate the agreement for convenience with advance notice. Either party may terminate for material breach or patent challenges.
- Co-funding Option: The Company may elect to co-fund clinical development for one licensed product (from the third or subsequent) to increase royalty tiers by a low single-digit percentage.
- Risk Factors: Investors are directed to the "Risk Factors" section of the Company's Form 10-Q for the period ended September 30, 2020, for a comprehensive list of uncertainties.
Key Facts for Investor Verification
- Confirmation of the closing date and receipt of the $100 million upfront payment and $35 million equity investment.
- Verification of the specific gene targets nominated by Lilly beyond the initial three.
- Monitoring of the Hart-Scott-Rodino waiting period status to ensure transaction closure.
- Review of the full Development and License Agreement and Stock Purchase Agreement filed as exhibits to the 2020 Form 10-K.
- Assessment of the impact of the 3,762,190 new shares on existing shareholder dilution.